MIV-210 - a potential drug against hepatitis B and HIV - enters phase II

02-Sep-2005

MIV-210 is a nucleoside analogue (NRTI) with potential in the treatment of HIV and hepatitis B (HBV). Good oral bioavailability (allowing administration as a tablet) and high plasma levels have been shown in phase I studies with MIV-210 in healthy volunteers.

Medivir has now initiated a phase IIa study including patients with multi-resistant HIV. The aim of the study is to establish the clinical efficacy of MIV-210 at a specific dose. In this study MIV-210 will be dosed during 2 weeks and is expected to be evaluated within 6 months.

"We are taking MIV-210 into phase II to test our hypothesis that MIV-210 in a relatively low dose has the capacity to help the growing group of HIV patients where current therapy is not sufficient. With positive results there is a big potential for MIV-210 within the HIV indication. In parallel we see possibilities for MIV-210 against another serious virus infection; hepatitis B" says Johan Harmenberg, VP Clinical Development in Medivir.

In pre-clinical trials MIV-210 has been shown to be an effective inhibitor of multi-resistant HIV strains as well as hepatitis B virus (HBV). In cell culture tests, MIV-210 has retained good activity on HBV which has become resistant against other drugs on the market.

In Medivir's opinion a favourable outcome of the newly initiated study would considerably increase the possibilities in finding a partner to the project prior to the further clinical development.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances